|Table of Contents|

Qingfei Tiaoqi decoction can reduce the immune checkpoint inhibitor-related adverse events in lung cancer patients by regulating the intestinal flora structure

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 05
Page:
890-895
Research Field:
Publishing date:

Info

Title:
Qingfei Tiaoqi decoction can reduce the immune checkpoint inhibitor-related adverse events in lung cancer patients by regulating the intestinal flora structure
Author(s):
WANG Xiao1; 2; CHEN Huachun3; HONG Weiling1; 2; YANG Yushun1; 2; 4; WANG Sheng3; WANG Chaoyue1; 2; HU Xiaoqin1; 2; WU Xiaoyu3
1.Jinhua Institute of Advanced Research,Zhejiang Jinhua 321000,China;2.College of Xingzhi,Zhejiang Normal University,Zhejiang Jinhua 321000,China;3.Zhejiang Jinhua Guangfu Cancer Hospital,Zhejiang Jinhua 321000,China;4.Nanjing University,Jiangsu Nanjing 210023,China.
Keywords:
traditional Chinese medicine; immunotherapy; adverse reactions; intestinal flora
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2024.05.018
Abstract:
Objective:To explore the influence of Qingfei Tiaoqi decoction(QFTQT) on the adverse reactions and intestinal flora structure of advanced non-small cell lung cancer(NSCLC) treated with immune checkpoint inhibitors (ICIs).Methods:Fifty-nine patients with advanced NSCLC(53 males and 6 females,aged 18~75 years) who planned to receive ICIs were randomly and double-blind divided into two groups:The intervention group(Chinese medicine group,n=29) provided Qingfei Tiaoqi decoction 200 mL/bid per immunotherapy cycle for 7 days.The control group(non-Chinese medicine group,n=30) did not provide Chinese medicine.The adverse reactions and clinical syndrome score of traditional Chinese medicine(SLEFI) before and after ICIs treatment in the two groups were evaluated and analyzed.In addition,10 patients in each group were randomly selected to collect stool samples,and the intestinal flora of V3-V4 region of 16S rRNA was sequenced using Illumina(San Diego,CA) MiSeq(PE2×300 bp) platform.Results:Immune checkpoint inhibitor-related adverse events(irAEs) in patients with advanced NSCLC treated with Qingfei Tiaoqi decoction were significantly lower than those in the control group,and were related to intestinal flora.Conclusion:Qingfei Tiaoqi decoction can effectively regulate irAEs in NSCLC patients by regulating the structure of intestinal flora.

References:

［1］张思维,郑荣寿,孙可欣,等.2016年中国恶性肿瘤分地区发病和死亡估计：基于人群的肿瘤登记数据分析［J］.中国肿瘤,2023,32(5):321-332. ZHANG SW,ZHENG RS,SUN KX,et al.Estimation of cancer incidence and mortality by area in China,2016:Population-based cancer registration data analysis［J］.Cancer in China,2023,32(5):321-332.
［2］罗添乐,罗斌,姚嘉良,等.肺癌免疫治疗的临床研究进展［J］.肿瘤学杂志,2021,27(1):74-79. LUO TL,LUO B,YAO JL,et al.Clinical research progress of immunotherapy for lung cancer［J］.Journal of Oncology,2021,27(1):74-79.
［3］杜静怡,徐兴祥.晚期非小细胞肺癌免疫治疗中面临的问题［J］.临床肺科杂志,2021,26(5):801-806,810. DU JY,XU XY.Challenges in immunotherapy of advanced non-small cell lung cancer［J］.Journal of Clinical Pulmonology,2021(5):801-806,810.
［4］任晓蕾,詹轶秋,张春燕,等.免疫检查点抑制剂安全性研究及不良反应防治［J］.中国药学杂志,2022,57(21):1855-1859. REN XL,ZHAN YQ,ZHANG CY,et al.Safety and prevention of adverse reactions of immune checkpoint inhibitors［J］.Chinese Journal of Pharmaceuticals,2022,57(21):1855-1859.
［5］陈方,梁海,程刚,等.替雷利珠单抗联合铂类治疗中晚期非小细胞肺癌的近期疗效和安全性研究［J］.临床和实验医学杂志,2023,22(6):583-587. CHEN F,LIANG H,CHENG G,et al.To evaluate the short-term efficacy and safety of tislelizumab combined with platinum in the treatment of advanced non-small cell lung cancer(NSCLC)［J］.Journal of Clinical and Experimental Medicine,2023,22(6):583-587.
［6］陆嘉宁,马佩,高雯,等.75岁以上癌症患者免疫治疗相关不良反应的回顾性分析［J］.南京医科大学学报(自然科学版),2023,43(5):640-647. LU JN,MA P,GAO W,et al.A retrospective analysis of immune-related adverse reactions in cancer patients over 75 years old［J］.Journal of Nanjing Medical University(Natural Science Edition),2023,43(5):640-647.
［7］GIULIA L,DOUWE VS,MARCO V,et al.Microbiota and cancer:The emerging beneficial role of bifidobacteria in cancer immunotherapy［J］.Frontiers in Microbiology,2020,11:1-18.
［8］王曦苇,靳桂霞.中医药调节肠道微生态的研究进展［J］.世界最新医学信息文摘,2018,18(6):203. WANG XW,JIN GX.Research progress of traditional Chinese medicine in regulating intestinal microecology［J］.Abstract of the Latest Medical Information in the World,2018,18(6):203.
［9］GONG YR,CHEN HZ,XIANG X,et al.Preliminary study on the traditional Chinese medicine treatment of immune-related adverse reactions of programmed cell death protein-1 and its ligand inhibitors［J］.Chinese Journal of Traditional Chinese Medicine,2022,37(11):6302-6305.
［10］KOMAROFF AL.The microbiome and risk for obesity and diabetes［J］.JAMA,2017,317(4):355.
［11］IIDA N,DZUTSEV A,STEWART CA,et al.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment［J］.Science,2013,342（Nov.22 TN.6161)：967-970.
［12］MIMA K,OGINO S,NAKAGAWA S,et al.The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms［J］.Surgical Oncology,2017,26(4)：368-376.
［13］YUAN J,CHEN C,CUI J,et al.Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae［J］.Cell Metabolism,2019,30(6):1172.
［14］邱树涛,武树奇,许宁宁,等.肠道病毒组在疾病中的治疗潜力及其机制研究进展［J］.微生物学通报,2023,50(11):5172-5189. QIU ST,WU SQ,XU NN,et al.Research progress on the therapeutic potential and mechanism of enterovirus in diseases［J］.Microbiology Bulletin,2023,50(11):5172-5189.
［15］邓寒丹,范兴丽.肠道菌群在肿瘤发生发展及免疫治疗中作用的研究进展［J］.生物工程学报,2022,38(6):2105-2119. DENG HD,FAN XL.Research progress on the role of intestinal flora in the occurrence and development of tumors and immunotherapy［J］.Chinese Journal of Biological Engineering,2022,38(6):2105-2119.
［16］闫珺,刘琼英,刘松江.肠道菌群参与癌症的治疗肠道菌群参与癌症的治疗［J］.现代肿瘤医学，2020，28（16）：2891-2894. YAN J,LIU QY,LIU SJ.Intestinal microflora in cancer treatment［J］.Modern Oncology，2020，28（16）：2891-2894.
［17］成鹏,杨宇,吴佳伟,等.肠道微生物对肿瘤发生发展及化疗药物的影响［J］.中国微生态学杂志,2020,32(7):849-852. CHENG P,YANG Y,WU JW,et al.Effects of gut microbiota on tumor development and chemotherapeutic drugs［J］.Chinese Journal of Microecology,2020,32(7):849-852.
［18］ZHANG JJ,LI WX,CUI XF,et al.Research progress of gut microbiota in inflammatory bowel disease［J］.Medical Review,2022,28(13):2537-2542.
［19］管理,陈洁.衰弱症干预的新角度：营养-肠道菌群-衰弱轴［J］.中国微生态学杂志,2022,34(9):1103-1106. GUAN L,CHEN J.A new perspective of frailty intervention:Nutrition-gut microbiota-frailty axis［J］.Chinese Journal of Microecology,2022,34(9):1103-1106.
［20］CHEVOLET I,SPEECKAERT R,SCHREUER M,et al.Characterization of the in vivo immune network of IDO,tryptophan metabolism,PD-L1,and CTLA-4 in circulating immune cells in melanoma［J］.Oncoimmunology,2015,4(3)：e982382-1-e982382-8.
［21］XU XR,FENG XR,HE M,et al.The effect of acupuncture on tumor growth and gut microbiota in mice inoculated with osteosarcoma cells［J］.Chinese Medicine,2020,15(10):1-15.

Memo

Memo:
浙江省基础公益研究计划（编号：LGD21C040001）；浙江省金华市中医药科学技术研究计划（编号：2022KY33）；金华高等研究院2023年教育教学研究课题（编号：B2023JY03）
Last Update: 2024-01-30